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Maturity-Onset Diabetes of the Young (MODY) is a monogenic form of diabetes, consisting of a heterogeneous
group of autosomal dominant inherited disorders. Typical onset is in individuals prior to twenty five years, and
presentation can mimic type 1 or 2 diabetes. Molecular genetic testing can allow precise identification of the
different MODY sub-types. Making a specific diagnosis of MODY can have important implications for the guidance
of appropriate treatment, prognosis and genetic counselling.
We present the cases of three children and their families diagnosed with MODY over the past two years. These
families highlight the features of three of the more common MODY subtypes, including two with novel mutations,
one of which segregates in a kindred that is strongly affected by both MODY and classic autoimmune mediated
diabetes. To date, we have identified a prevalence of MODY in the paediatric diabetes population of the lower
South Island, New Zealand, of approximately 2.5%. This prevalence, along with increasing access to molecular
genetic testing, highlights the importance of consideration of MODY in atypical diabetes presentations in the
paediatric/adolescent population.
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Maturity Onset Diabetes of the Young (MODY) is a
monogenic form of diabetes. It consists of a heteroge-
neous group of autosomal dominant inherited disorders,
with typical onset in individuals aged less than twenty
five years [1,2]. There are several sub-types of MODY
which can be precisely identified using molecular genetic
testing, the four most common of which [3] are outlined
in Table 1 (in descending order of frequency). Modes of
presentation vary and can mimic either type 1 or 2 dia-
betes. Making a specific diagnosis of MODY can have
important implications for the guidance of appropriate
treatment, prognosis and genetic counselling.* Correspondence: ben.wheeler@otago.ac.nz
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reproduction in any medium, provided the orThe Southern District Health Board paediatric diabetes
team provides sole care for approximately 160 children
and adolescents spread over the largest geographical re-
gion in New Zealand. In this report we present three
children and their families who have been diagnosed
with MODY over the past two years. We identified two
novel mutations and a kindred strongly affected by both
MODY and classic autoimmune-mediated diabetes.Case presentation
Case 1
A 9 year old Caucasian boy with a BMI of 19 kg/m2
(z-score 1.5) presented in 2006 with mild diabetes (two in-
dependent fasting blood glucose levels (BGL) >7.0 mmol/
L), and was both autoantibody-negative and non-insulin
resistant, requiring no immediate treatment. He was ini-
tially lost to follow up, but represented in 2010 aged 13
years, along with his sister aged 11 years. Both were
asymptomatic but had on-going mild hyperglycaemia
(Figure 1). The persistent mild hyperglycaemia, combinedl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 MODY subtypes (4 most common in descending order of frequency)
Gene and MODY subtype Gene function + phenotype Prognosis
HNF1-alpha gene Regulates insulin gene transcription Progressive
(MODY 3) Reduced insulin secretion/diabetes and marked sensitivity to sulfonylurea May require insulin
May develop secondary complications
Glucokinase (GCK) gene Catalyses conversion of glucose to glucose-6-phosphate Generally non or slowly progressive
(MODY 2) Reduced glucose sensing by beta cells – Mild diabetes Complications rare
HNF4-alpha gene Nuclear transcription factor that regulates hepatic and pancreatic beta cell
gene expression
Progressive
(MODY 1) Reduced insulin secretion/diabetes and marked sensitivity to sulfonylurea May require insulin
May develop secondary complications
HNF1-beta gene Regulates HNF4á gene transcription Progressive beta-cell failure with diabetes
onset around puberty
(MODY 5) Insulin resistance + wide clinical spectrum Insulin resistance without obesity
+/− Urogenital/pancreatic anomalies Insulin dependence
+/− Pancreatic exocrine failure
+/− Developmental delay/Learning difficulties
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two diabetes (T2DM), led to gene screening for a
glucokinase (GCK) gene abnormality (MODY 2 subtype).
Complicating matters were family members with proven
antibody positive (glutamate decarboxylase (GAD) posi-
tive) type one diabetes (T1DM), with associated com-
plications. A novel mutation was subsequently identified
(Figure 2) in exon 7 of the glucokinase (GCK) gene, in
multiple individuals from this kindred (Figure 3). A mater-
nal uncle with latent autoimmune diabetes (LADA) (GAD
positive) was identified with this mutation. These children
remain well without treatment. Regarding case one, his
HbA1c is currently 42 mmol/mol (6%).
Case 2
A 14 yr old Cook Island Maori girl with a BMI of 23 kg/m2
(z-score 1.1) presented with severe non-ketoticFigure 1 Typical BGLs on continuous glucose monitoring - case 1.hyperglycaemia (BGL 71.7 mmol/L (NR 4–6)) and hyper-
natraemic dehydration (corrected Na 150 mmol/L (135–
145), serum osmolality 364 mosm/kg (275–295)), pH 7.39,
and lactate of 5.3 mmol/L (NR 0.5-2). There was evidence
of insulin resistance with fasting insulin 336 pmol/L (10–
80), C-peptide 1180 pmol/L (350–750), and clinical
acanthosis nigricans. Insulin autoantibodies were negative.
She had moderate, unexplained intellectual disability with
some subtle dysmorphic facial features. There was an ex-
tensive family history of T2DM (Figure 4). Initial treat-
ment consisted of insulin up to 3 units/kg/day. A
microarray study (Agilent ISCA (v2) 60 K whole genome
array) demonstrated a novel 1.3 Mb deletion at chromo-
some 17q12, this segment includes the HNF1β and mul-
tiple other genes. Thus, there is a haplo-insufficiency of
HNF1β. Parental studies were normal, showing this to be
a de novo deletion. Mutation within the HNF1β gene may
Figure 2 One copy of the variant c.698G>A (p.Cys233Tyr) in exon
7 of the GCK gene (Refseq accession number NM_000162).
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and pelvic ultrasonography were normal. The intellectual
disability and subtle facial dysmorphism may also be due
to the loss of other genes within this deleted segment.
Currently her HbA1c is 48 nmmol/mol (6.5%) on insulin
1.25 units/kg/day and 500 mg TDS Metformin.Case 3
An 11 yr old Caucasian girl with a BMI of 16 kg/m2 (z-
score −1.2) presented with a 4 month history of recurrentMODY, Presumed MODY
Figure 3 Family tree - case 1.mucosal candidiasis and mild postprandial hypergly-
caemia. Diabetes was confirmed with two random BGLs
>11.1 mmol/l. She was well on presentation with a blood
pH 7.33, and negative for ketones. Diabetes autoantibody
screening was negative, as were clinical and biochemical
signs of insulin resistance. Insulin was commenced but
her requirement was low at 3 units of isophane daily with
aspart as needed with meals (<2 units/day). A significant
family history was uncovered (Figure 5) and an HNF1α
(MODY 3) gene mutation was suspected and subse-
quently confirmed on molecular genetic testing (Figure 6).
Currently, she is well controlled on Gliclazide 80 mgmane
with an HbA1c of 51 mmol/mol (6.8%).
Discussion
In the past two years we have identified four children
and their families with MODY, covering three subtypes.
In each of these cases the diagnosis of MODY has been
confirmed by molecular genetic testing. We have identi-
fied two novel gene mutations, one in the GCK gene
(MODY 2), and one in the HNF1β gene (MODY 5).
Clinically, there is diverse range of presentation for
MODY subtypes, with our cases highlighting some of
this phenotypic variation.
Making a diagnosis of MODY has important implica-
tions for treatment, prognosis, and genetic counselling.
Glucokinase gene mutations (MODY 2) often require no
treatment [1,2]. In case one, making this diagnosis has
led to: reassurance; reduced monitoring; re-diagnosis of
many family members; and subsequent acceptance of
no treatment for most. HNF1α (MODY 3) and HNF4α
(MODY 1) gene mutations usually have a marked sensi-
tivity to oral sulfonylureas [1,2,4]. For case three this
allowed for cessation of insulin therapy. Unfortunately,
as in the father of this patient, an insulin requirement
often develops as the disease progresses [5]. In case,          T2DM, T1DM/LADA
MODY, Presumed MODY,          T2DM, T1DM/LADA
Figure 4 Case 2 - Family tree.
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to an explanation of a previously unexplained pheno-
type, as well as guidance for screening for associated
abnormalities.
Case one also highlights the rare occurrence of a kin-
dred that is strongly affected by both MODY and classic
autoimmune mediated diabetes. One member of this fam-
ily now has diabetes consistent with LADA (GAD +ve)
combined with the novel GCK gene mutation. This is
extremely rare, occurring in <1% of MODYcases [6].
To date (based on these four cases) the Otago/South-
land regions in the south of New Zealand have a paediat-
ric MODY prevalence of 2.5% in children with diabetes.MODY, Presumed MODY
Figure 5 Case 3 – family tree.While this is based on very small numbers, there is no
other data currently published for New Zealand or
Australia on MODY prevalence. While similar to the 2.4%
paediatric rate reported by Galler et al. [7] for Saxony
(Germany), this appears high compared to some world-
wide clinic reports [8-10]. Given current estimates of
prevalence in adult diabetes of 2-5% [1], it is likely that
many MODYcases remain undiagnosed in both paediatric
and adult clinics [3,11]. Vigilance should remain particu-
larly for those with two or more atypical clinical features,
such as: no features of insulin resistance; negative β cell
autoimmunity; non-ketotic presentations; a strong family
history of diabetes (any type); no or unusually low insulin,          T2DM, T1DM/LADA
Figure 6 Frameshift mutation c.864delGinsCC, or c.864G>C and c.872dupC, (p.Gly292ArgfsX25) in exon 4 of the HNF1α gene (Refseq
accession number NM_000545).
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or atypical associated phenotypes [1,2,4].Conclusions
In conclusion, our local prevalence, along with increas-
ing access to molecular genetic testing, highlights the
importance of considering MODY in atypical diabetes
presentations in the paediatric and adolescent diabetes
populations.Consent
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